Article in EMBO reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Stephan H SpangenbergHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.ORCID 0009-0007-5822-505X
Nicholas GaraffoDepartment of Biological and Biomedical Sciences, Harvard Medical School, Boston, MA, USA.ORCID 0009-0005-6344-3874
Enya Marie Catherine AlcindorHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.ORCID 0009-0002-8575-9595
Benjamin LuskHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.
Vijaya PandeyDepartment of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Adam D LonghurstHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.
Emma BolechHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.ORCID 0009-0006-4656-3636
Luke A GilbertHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0001-5854-0825
James A WohlschlegelDepartment of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
David P ToczyskiHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA. david.toczyski@ucsf.edu.ORCID 0000-0001-5924-0365
Funding
Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Alan Ashworth · 1999 to 2026
$209.7M
Molecular and Cellular Mechanisms in CancerT32CA108462 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOGA, ANDREI · 2004 to 2024
$10.4M
Spatial multiomic mapping of gene function with CRISPRoffUM1HG012660 · NHGRI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Luke Gilbert · 2022 to 2026
$8.2M
Regulation by post-translation modifications in response to stressR35GM118104 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI TOCZYSKI, DAVID PAUL · 2016 to 2025
$7.2M
A GENETIC INTERACTION MAP OF THE HUMAN NUCLEUSDP2CA239597 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GILBERT, LUKE · 2018 to 2018
$2.4M
Understanding Ubiquitin-dependent Regulation of Iron Metabolism using Mass SpectrometryR35GM153408 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI James Akira Wohlschlegel · 2024 to 2026
$1.2M
HHS | NIH | National Cancer Institute (NCI) NIH DP2CA239597HHS | NIH | National Cancer Institute (NCI) P30CA082103HHS | NIH | National Cancer Institute (NCI) T32CA108462HHS | NIH | National Human Genome Research Institute (NHGRI) UM1HG012660HHS | NIH | National Institute of General Medical Sciences (NIGMS) R35 GM118104HHS | NIH | National Institute of General Medical Sciences (NIGMS) R35 GM153408NCI NIH HHS DP2 CA239597NCI NIH HHS P30 CA082103NCI NIH HHS T32 CA108462NHGRI NIH HHS UM1 HG012660NIGMS NIH HHS R35 GM118104NIGMS NIH HHS R35 GM153408Pew-Stewart Scholars Pew-Stewart Scholars for Cancer Research awardUniversity of California, San Francisco (UCSF) RAP Program
6 · The paper itself
Abstract
FBXO42 is a poorly characterized F-box protein essential in 15% of cancer cell lines from diverse lineages. High-throughput approaches indicate that FBXO42 function correlates with that of coiled-coil protein CCDC6, and that the two proteins interact physically, but the relationship between them is not understood. We show that FBXO42 ubiquitinates PPP4C (protein phosphatase 4 catalytic subunit) and negatively regulates its expression. FBXO42 binds PPP4C independently of CCDC6. Similarly, we show that CCDC6 physically interacts with PPP4C independently of FBXO42, and identify a PPP4C binding site within CCDC6. However, mutation of CCDC6 does not reduce PPP4C ubiquitination, suggesting that FBXO42 and CCDC6 bind and regulate PPP4C through separate mechanisms. Viability of an FBXO42- and CCDC6-dependent glioblastoma cell line is rescued when PPP4C is knocked down along with FBXO42 or CCDC6, suggesting that aberrant activation of PPP4C is a driver of cell death when FBXO42 or CCDC6 activity is compromised. These findings tie together previous data suggesting that FBXO42 functions with CCDC6 by providing mechanistic insight into their independent regulation of PP4.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The regulation of protein phosphatase 4 by FBXO42 is required for cancer cell survival. · full record | OpenQuestion